FDA Approves Pfizer’s ABRYSVO Vaccine for the Prevention of RSV

FDA Approves Pfizer’s ABRYSVO Vaccine for the Prevention of RSV

Pfizer’s ABRYSVO, a respiratory syncytial virus (RSV) vaccine, has been approved by the U.S. Food and Drug Administration for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by RSV in infants from birth up to 6 months of age by active immunization of pregnant women at 32 through 36 weeks gestational age.

Inverse Vaccine May Reverse Autoimmune Diseases

Researchers from the Pritzker School of Molecular Engineering at the University of Chicago have developed a new type of vaccine called an “inverse vaccine that completely reversed autoimmune diseases without fully shutting down the rest of the immune system.

Study Finds Meningitis Vaccine Shows Promise

According to a new study, a meningitis vaccine tested in two African countries has shown promise in the fight against the disease, eliciting immune responses against five main strains. The Phase III randomized trials were conducted on 1,800 people in the West African nations of Mali and The Gambia. The under-trial NmCV-5 vaccine, developed by […]